MarketCap
Facebook
X
TelegramGeschäftsbericht 2025
hinzugefügt 11.04.2026
Immutep Limited Betriebsaufwand 2011-2026 | IMMP
Betriebsaufwand Jährlich Immutep Limited
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | - | - | 16.6 M | 16.9 M | 20.5 M | 22.7 M | - |
Alle Zahlen in AUD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 22.7 M | 16.6 M | 19.2 M |
Betriebsaufwand anderer Aktien in der Pharmaeinzelhändler
| Name | Betriebsaufwand | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
432 M | - | 2.43 % | $ 254 M |  Germany |
 |
Aligos Therapeutics
ALGS
|
90.2 M | $ 8.48 | 6.0 % | $ 83.8 M |  USA |
 |
Alterity Therapeutics Limited
ATHE
|
16.7 M | $ 3.66 | -1.48 % | $ 8.81 B |  Australia |
 |
I-Mab
IMAB
|
1.49 B | - | - | $ 866 M |  China |
 |
AlloVir
ALVR
|
46.2 M | - | 4.14 % | $ 49.1 M | USA |
 |
Applied Molecular Transport
AMTI
|
127 M | - | - | $ 10.1 M | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
2.66 B | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
78.3 M | - | 2.54 % | $ 160 B |  France |
 |
Esperion Therapeutics
ESPR
|
343 M | $ 2.19 | 0.92 % | $ 455 M | USA |
 |
Evogene Ltd.
EVGN
|
13.8 M | $ 0.78 | -4.39 % | $ 27.9 M |  Israel |
 |
Applied Therapeutics
APLT
|
74.5 M | - | - | $ 8.42 M | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
8.22 M | - | -1.52 % | $ 24.7 M | USA |
 |
Midatech Pharma plc
MTP
|
4.78 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Genmab A/S
GMAB
|
67.9 M | $ 28.2 | -0.18 % | $ 18 B |  Danmark |
 |
Grifols, S.A.
GRFS
|
1.64 B | $ 8.38 | 2.01 % | $ 6.83 B |  Spain |
 |
GT Biopharma
GTBP
|
21.3 M | $ 0.38 | 2.47 % | $ 2.1 M | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
216 M | $ 21.28 | 4.44 % | $ 995 M | USA |
 |
Halozyme Therapeutics
HALO
|
218 M | $ 66.92 | -1.33 % | $ 8.02 B | USA |
 |
Acorda Therapeutics
ACOR
|
206 M | - | -24.86 % | $ 820 K | USA |
 |
Институт стволовых клеток человека
ISKJ
|
629 M | - | - | - |  Russia |
 |
Adverum Biotechnologies
ADVM
|
140 M | - | - | $ 86.2 M | USA |
 |
Harmony Biosciences Holdings
HRMY
|
462 M | $ 29.05 | 0.55 % | $ 1.67 B | USA |
 |
Advaxis
ADXS
|
22 M | - | -9.65 % | $ 45.9 M | USA |
 |
Aeterna Zentaris
AEZS
|
13.3 M | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
24.2 M | - | -10.17 % | $ 12.2 K | USA |
 |
Incyte Corporation
INCY
|
1.62 B | $ 95.33 | -0.77 % | $ 18.6 B | USA |
 |
Aeglea BioTherapeutics
AGLE
|
210 M | - | - | $ 1.01 B | USA |
 |
Akebia Therapeutics
AKBA
|
173 M | $ 1.46 | 4.29 % | $ 375 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
66.5 M | - | - | $ 26.5 M | USA |
 |
Allakos
ALLK
|
196 M | - | - | $ 28.6 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
14 M | $ 2.99 | 2.4 % | $ 4.92 M | Israel |
 |
Aptinyx
APTX
|
62.6 M | - | -39.0 % | $ 4.57 M | USA |
 |
Aquestive Therapeutics
AQST
|
85.5 M | $ 4.2 | 2.82 % | $ 449 M | USA |
 |
Aravive
ARAV
|
80 M | - | -13.39 % | $ 1.45 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
137 M | $ 24.24 | 0.1 % | $ 3.08 B | USA |
 |
Innate Pharma S.A.
IPHA
|
63 M | $ 1.47 | 4.26 % | $ 235 M | France |
 |
AIkido Pharma
AIKI
|
179 M | - | 1.93 % | $ 17.4 M | USA |
 |
Celldex Therapeutics
CLDX
|
58.1 M | $ 32.59 | 1.09 % | $ 2.16 B | USA |
 |
Autolus Therapeutics plc
AUTL
|
145 M | $ 1.48 | -0.67 % | $ 394 M | Britain |
 |
Aptose Biosciences
APTO
|
24.7 M | - | -45.71 % | $ 1.2 M | Canada |
 |
Cidara Therapeutics
CDTX
|
177 M | - | - | $ 1.41 B | USA |
 |
AVROBIO
AVRO
|
71.7 M | - | 1083.1 % | $ 745 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
29.8 M | - | - | $ 7.46 M | Israel |
 |
AstraZeneca PLC
AZN
|
17.6 B | - | - | $ 96.9 B | Britain |
 |
Akero Therapeutics
AKRO
|
80.2 M | - | - | $ 3.67 B | USA |
 |
CureVac N.V.
CVAC
|
88.9 M | - | - | $ 867 M | Germany |
 |
Brainstorm Cell Therapeutics
BCLI
|
31.7 M | - | -2.5 % | $ 5.88 M | USA |
 |
BeiGene, Ltd.
BGNE
|
390 M | - | 0.49 % | $ 251 B |  Cayman-islands |